Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Novo Nordisk: The Strength To Withstand Challenges
Novo Nordisk's price has regained momentum in recent weeks after seeing a big slump earlier in 2025. With strong financials, and robust profit estimates even after a downgrade in outlook, NVO could continue to rise. There are risks to the stock as well, though, from losing market share to compounder versions of its blockbuster GLP-1 drugs.
The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars
Novo Nordisk's annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
After ousting CEO, Novo Nordisk reclaims crown as largest European company
Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization.
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
Novo Nordisk (NVO) concluded the recent trading session at $81.05, signifying a +2.95% move from its prior day's close.
NVO Stock Gains After Parvus Asset Management Builds Stake
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
Novo Nordisk: The Time To Buy Has Come
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient investors. Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market, despite revised guidance due to compounded drug impacts. NVO actively combats compounded GLP-1s via legal routes, new patient access programs like $499 Wegovy, and key formulary wins such as CVS exclusivity.
Novo Nordisk shares rise 3% after reported activist stake-building
Shares in Novo Nordisk (NYSE:NVO), maker of fat-busting jabs such as Ozempic, jumped 3% after the emergence of an activist investor on its share register. Parvus Asset Management is building a stake in the Danish drug giant, according to the Financial Times, amid investor unease over the company's position in the competitive weight-loss drug market.
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk A/S NYSE: NVO, Lars Fruergaard Jørgensen is on the outs. On May 16, Novo made the announcement that Jørgensen would step down.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
